Savara (NASDAQ:SVRA) Stock Price Down 6.5%

Savara Inc (NASDAQ:SVRA)’s share price fell 6.5% during mid-day trading on Thursday . The company traded as low as $4.62 and last traded at $4.63. 804,305 shares traded hands during trading, a decline of 6% from the average session volume of 860,189 shares. The stock had previously closed at $4.95.

Analyst Upgrades and Downgrades

SVRA has been the subject of several research analyst reports. Piper Sandler lifted their price objective on shares of Savara from $7.00 to $16.00 and gave the company an “overweight” rating in a research note on Monday, March 4th. JMP Securities restated a “market outperform” rating and issued a $8.00 price target on shares of Savara in a report on Thursday, April 18th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $8.20.

Savara Stock Performance

The company has a debt-to-equity ratio of 0.19, a current ratio of 15.66 and a quick ratio of 15.66. The company has a fifty day moving average price of $4.91 and a 200 day moving average price of $4.46. The stock has a market cap of $646.68 million, a P/E ratio of -15.00 and a beta of 0.73.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.02. On average, equities analysts expect that Savara Inc will post -0.38 EPS for the current year.

Hedge Funds Weigh In On Savara

Several large investors have recently added to or reduced their stakes in the business. AJOVista LLC purchased a new position in Savara during the 4th quarter worth $40,000. Principal Financial Group Inc. bought a new position in shares of Savara during the third quarter valued at about $48,000. Kestra Private Wealth Services LLC purchased a new position in Savara during the third quarter worth about $64,000. China Universal Asset Management Co. Ltd. bought a new stake in Savara in the 4th quarter worth about $74,000. Finally, Tower Research Capital LLC TRC increased its stake in Savara by 665.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 19,507 shares of the company’s stock valued at $92,000 after buying an additional 16,959 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.